CO2021011553A2 - Síntesis de 4-amino-5-metil-1h-piridin-2 (1h) -on (compuesto intermedio para la síntesis del antagonista finerenona de mr) a partir de 2-cloro-5-metil-4-nitro-piridina-1-óxido usando el compuesto intermedio 2-cloro-5-metil-4-piridinamina - Google Patents
Síntesis de 4-amino-5-metil-1h-piridin-2 (1h) -on (compuesto intermedio para la síntesis del antagonista finerenona de mr) a partir de 2-cloro-5-metil-4-nitro-piridina-1-óxido usando el compuesto intermedio 2-cloro-5-metil-4-piridinaminaInfo
- Publication number
- CO2021011553A2 CO2021011553A2 CONC2021/0011553A CO2021011553A CO2021011553A2 CO 2021011553 A2 CO2021011553 A2 CO 2021011553A2 CO 2021011553 A CO2021011553 A CO 2021011553A CO 2021011553 A2 CO2021011553 A2 CO 2021011553A2
- Authority
- CO
- Colombia
- Prior art keywords
- methyl
- chloro
- synthesis
- amino
- finerenone
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pyridine Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
La presente invención se refiere a un nuevo y mejorado procedimiento para la preparación de 4–amino–5–metilpiridona de la fórmula (I) (I) que representa un producto intermedio para la preparación del antagonista MR finerenona.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19160904 | 2019-03-05 | ||
PCT/EP2020/055292 WO2020178175A1 (de) | 2019-03-05 | 2020-02-28 | Synthese von 4-amino-5-methyl-1h-pyridin-2(1h)-on (zwischenverbindung der synthese des mr antagonisten finerenone) aus 2-chloro-5-methyl-4-nitro-pyridine-1-oxid über die zwischenverbindung 2-chloro-5-methyl-4-pyridinamin |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2021011553A2 true CO2021011553A2 (es) | 2021-09-20 |
Family
ID=65991501
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2021/0011553A CO2021011553A2 (es) | 2019-03-05 | 2021-08-31 | Síntesis de 4-amino-5-metil-1h-piridin-2 (1h) -on (compuesto intermedio para la síntesis del antagonista finerenona de mr) a partir de 2-cloro-5-metil-4-nitro-piridina-1-óxido usando el compuesto intermedio 2-cloro-5-metil-4-piridinamina |
Country Status (16)
Country | Link |
---|---|
US (1) | US20220153699A1 (es) |
EP (1) | EP3935045A1 (es) |
JP (1) | JP2022523986A (es) |
KR (1) | KR20210135238A (es) |
CN (1) | CN113474332A (es) |
AU (1) | AU2020230965A1 (es) |
BR (1) | BR112021014815A2 (es) |
CA (1) | CA3132399A1 (es) |
CL (1) | CL2021002316A1 (es) |
CO (1) | CO2021011553A2 (es) |
IL (1) | IL285937A (es) |
JO (1) | JOP20210242A1 (es) |
MX (1) | MX2021010612A (es) |
PE (1) | PE20212199A1 (es) |
SG (1) | SG11202109546RA (es) |
WO (1) | WO2020178175A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3935044B1 (de) * | 2019-03-05 | 2023-04-12 | Bayer Aktiengesellschaft | Verfahren zur herstellung von 4-amino-5-methylpyridon |
CN114656400A (zh) * | 2022-04-26 | 2022-06-24 | 浙江科聚生物医药有限公司 | 一种非奈利酮关键中间体的制备方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1311185A (zh) * | 2000-03-03 | 2001-09-05 | 山东新华制药股份有限公司 | 4-氨基吡啶及衍生物的制备方法 |
WO2005100342A1 (en) | 2004-03-26 | 2005-10-27 | Vertex Pharmaceuticals, Incorporated | Pyridine inhibitors of erk2 and uses thereof |
DE102007009494A1 (de) | 2007-02-27 | 2008-08-28 | Bayer Healthcare Ag | Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung |
CN103193704B (zh) * | 2013-04-12 | 2016-03-09 | 四川铂瑞生物医药有限公司 | 2-羟基-4-氨基-5-甲基吡啶杂环化合物 |
AU2015295376C1 (en) | 2014-08-01 | 2020-07-16 | Bayer Pharma Aktiengesellschaft | Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carbox-amide and the purification thereof for use as an active pharmaceutical ingredient |
-
2020
- 2020-02-28 WO PCT/EP2020/055292 patent/WO2020178175A1/de active Application Filing
- 2020-02-28 MX MX2021010612A patent/MX2021010612A/es unknown
- 2020-02-28 US US17/435,606 patent/US20220153699A1/en active Pending
- 2020-02-28 KR KR1020217027997A patent/KR20210135238A/ko unknown
- 2020-02-28 AU AU2020230965A patent/AU2020230965A1/en not_active Abandoned
- 2020-02-28 JO JOP/2021/0242A patent/JOP20210242A1/ar unknown
- 2020-02-28 PE PE2021001422A patent/PE20212199A1/es unknown
- 2020-02-28 SG SG11202109546RA patent/SG11202109546RA/en unknown
- 2020-02-28 EP EP20706521.0A patent/EP3935045A1/de active Pending
- 2020-02-28 CN CN202080013586.9A patent/CN113474332A/zh active Pending
- 2020-02-28 BR BR112021014815-9A patent/BR112021014815A2/pt not_active Application Discontinuation
- 2020-02-28 CA CA3132399A patent/CA3132399A1/en active Pending
- 2020-02-28 JP JP2021552653A patent/JP2022523986A/ja active Pending
-
2021
- 2021-08-29 IL IL285937A patent/IL285937A/en unknown
- 2021-08-31 CO CONC2021/0011553A patent/CO2021011553A2/es unknown
- 2021-09-03 CL CL2021002316A patent/CL2021002316A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP3935045A1 (de) | 2022-01-12 |
KR20210135238A (ko) | 2021-11-12 |
SG11202109546RA (en) | 2021-09-29 |
BR112021014815A2 (pt) | 2021-09-28 |
US20220153699A1 (en) | 2022-05-19 |
CL2021002316A1 (es) | 2022-04-08 |
JP2022523986A (ja) | 2022-04-27 |
WO2020178175A1 (de) | 2020-09-10 |
CN113474332A (zh) | 2021-10-01 |
MX2021010612A (es) | 2021-09-28 |
IL285937A (en) | 2021-10-31 |
AU2020230965A1 (en) | 2021-09-23 |
CA3132399A1 (en) | 2020-09-10 |
JOP20210242A1 (ar) | 2023-01-30 |
PE20212199A1 (es) | 2021-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201890522A1 (ru) | Способ получения противогрибковых соединений | |
CO2021011553A2 (es) | Síntesis de 4-amino-5-metil-1h-piridin-2 (1h) -on (compuesto intermedio para la síntesis del antagonista finerenona de mr) a partir de 2-cloro-5-metil-4-nitro-piridina-1-óxido usando el compuesto intermedio 2-cloro-5-metil-4-piridinamina | |
EA201992235A1 (ru) | Синтез ингибитора mcl-1 | |
MY201524A (en) | Novel compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same | |
MX2020004917A (es) | Procesos para la resolucion de los derivados de la benzodiazepina-2-ona y de la benzoazepin-2-ona. | |
CO2017012403A2 (es) | Proceso para preparar 4-amino-piridazinas | |
EP3828186A3 (en) | Pyrimidinones as factor xia inhibitors | |
MX2016016297A (es) | Procedimientos para la preparacion de compuestos antivirales. | |
BR112013018732A2 (pt) | novos derivados de amida de aril-benzocicloalquila | |
PH12014502586A1 (en) | Novel ring-substituted n-pyridinyl amides as kinase inhibitors | |
BR112018011788A2 (pt) | formas sólidas de éster etílico de ácido (2r,4s)-5-(bifenil-4-il)-4-[(3-carboxipropionil)amino]-2-metil-pentanoico, seus sais e um método de preparação | |
EA201691031A1 (ru) | Синтез макроциклического трипептида, ингибирующего hcv ns3 | |
CL2020001589A1 (es) | Proceso para la preparación de derivados de quinolina. | |
WO2016063294A3 (en) | Process for the preparation of (r)-3-(4-(7h-pyrrolo[2,3-d], pyrimidin-4-yl)-1 h-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate and its polymorphs thereof | |
SA520411406B1 (ar) | مركبات مثبطة لمستقبل حمض ليسوفوسفاتيديك 1 | |
EA201892515A1 (ru) | Стероидные 6,7-бета-эпоксиды в качестве интермедиатов | |
EA201992421A1 (ru) | Способ получения озанимода | |
MX2016009123A (es) | Composicion agroquimica. | |
EA201891769A1 (ru) | СПОСОБ ПОЛУЧЕНИЯ СОЕДИНЕНИЯ ПИРРОЛО[3,2-d]ПИРИМИДИНА И ПРОМЕЖУТОЧНЫХ СОЕДИНЕНИЙ | |
ZA202204803B (en) | An efficient new process for synthesis of 2-amino-5-chloro-n-,3-dimethylbenzamide | |
CL2018002344A1 (es) | Proceso para preparar compuestos de 7h-pirrolo[2,3-d]pirimidina | |
ECSP21088515A (es) | Compuestos de pirrolidina | |
EA202090933A1 (ru) | Способ получения гербицидных соединений пиридазинона | |
SA520412408B1 (ar) | عملية تحضير مركبات ثنائي أريل أوكسي بنزو ديازول غير متجانسة مزدوجة الاستبدال | |
CU20120065A7 (es) | Derivado de 4-[etil(dimetil)amonio] butanoato para el tratamiento de enfermedades cardiovasculares y sus métodos de obtención |